A multicenter, prospective, phaseⅡ, single-arm study on the treatment of newly diagnosed multiple myeloma with domestic bortezomib in combination with lenalidomide and dexamethasone

• Published in: Zhōnghuá xuèyèxué zázhì 2024-06, Vol.45 (6), p.571
• Main Authors: Xie, L N, Wang, X, He, Q, Wang, H, Ma, J, Zhang, H Y, Liu, N, Jie, G T, Xiao, T W, Zhang, H, Zhang, H G, Li, Z J, Xing, L J
• Format: Article
• Language: Chinese
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bortezomib - administration & dosage; Dexamethasone - administration & dosage; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide - administration & dosage; Male; Middle Aged; Multiple Myeloma - diagnosis; Multiple Myeloma - drug therapy; Prognosis; Prospective Studies; Treatment Outcome
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.cn121090-20231217-00318

To explore the efficacy and safety of domestic bortezomib in combination with lenalidomide and dexamethasone in the treatment of newly diagnosed multiple myeloma (NDMM) . This multicenter, prospective, single-arm clinical study included 126 patients with NDMM admitted to seven hospitals between December 2019 and January 2022. All patients received domestic bortezomib in combination with lenalidomide and dexamethasone (BLD regimen), and the efficacy, prognostic factors, and safety were analyzed. Among the 126 patients with NDMM, 118 completed four cycles of treatment, with an overall response rate (ORR) of 93.22% (110/118) and a ≥very good partial response (VGPR) rate of 68.64% (81/118). Ultimately, 114 patients completed at least eight cycles of treatment, with an ORR of 92.98% (106/114) and a ≥VGPR rate of 77.19% (88/114). Eighteen patients underwent autologous hematopoietic stem cell transplantation after completing 6-8 cycles of the BLD regimen, with an ORR of 100% (18/18) and a ≥VGPR rate of 88.9% (16/18)